8-KOther EventsExhibits & Filings

Cencora, Inc. 8-K Report, Corporate Update (Aug 1, 2012)

Filed August 1, 2012For Securities:COR

Summary

AmerisourceBergen Corporation (now Cencora, Inc.) has announced a significant three-year agreement to supply pharmaceuticals to Express Scripts, a major pharmacy benefit manager. This contract, effective October 1, 2012, is valued at approximately $18.5 billion annually and is expected to represent a substantial portion of the company's revenue. While the agreement is a key development, management has indicated it will not impact the company's fiscal year 2012 financial outlook or its preliminary fiscal year 2013 expectations, which were previously communicated. This contract award is a crucial event for AmerisourceBergen, highlighting its strong position in the pharmaceutical distribution market and its strategic relationship with a key customer. Investors should monitor the execution of this agreement and its ongoing contribution to the company's financial performance in the coming years. The company's ability to secure such a large contract demonstrates its competitive capabilities and market influence.

Key Highlights

  • 1AmerisourceBergen Corporation signed a three-year agreement with Express Scripts to supply approximately $18.5 billion in pharmaceuticals annually.
  • 2The new contract is set to commence on October 1, 2012.
  • 3This agreement is projected to account for approximately 23% of AmerisourceBergen's total revenues.
  • 4The contract is expected to contribute about 3% to the company's earnings per share.
  • 5Management confirmed that this contract award has no impact on the company's fiscal year 2012 financial expectations.
  • 6The award also does not affect the preliminary fiscal year 2013 expectations previously disclosed by the company.
  • 7A news release detailing the agreement was issued on July 31, 2012, and is filed as an exhibit.

Frequently Asked Questions

This 8-K filing announces a material event: AmerisourceBergen Corporation (now Cencora, Inc.) entering into a significant three-year pharmaceutical supply agreement with Express Scripts, effective October 1, 2012.

The contract is expected to generate approximately $18.5 billion in annual revenue, representing about 23% of AmerisourceBergen's total revenue. It is also anticipated to contribute approximately 3% to the company's earnings per share.

No, the company has stated that this contract award has no impact on its financial expectations for fiscal year 2012 and its preliminary expectations for fiscal year 2013.

The agreement is effective starting October 1, 2012.